Andrea Pettenuzzo

Andrea Pettenuzzo

Auto-generated profile, based on publicly available information

Andrea Pettenuzzo

School of Biological and Chemical Sciences University of Galway University Road Galway H91 TK33 Ireland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2021 in Chemistry – A European Journal
Verified
Journal Article
Open access
PDF file
MGMaria Gil‐Moles
Maria Gil‐Moles
STSebastian Türck
Sebastian Türck
UBUttara Basu
Uttara Basu
APAndrea Pettenuzzo
Andrea Pettenuzzo
SBSaurav Bhattacharya
Saurav Bhattacharya
IOIngo Ott
Ingo Ott
The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has called for an urgent need for dedicated antiviral therapeutics. Metal complexes are commonly underrepresented in compound libraries that are used for screening in drug discovery campaigns, however, there is growing evidence for their role in medicinal chemistry. Based on previous results, we have selected more than 100 structurally diverse metal complexes for profiling as inhibitors of two relevant SARS‐CoV‐2 replication mechanisms, namely the interaction of the spike (S) protein with the ACE2 receptor and the papain‐like protease PLpro. In addition to many well‐established types of mononuclear experimental metallodrugs, the pool of compounds tested was extended to approved metal‐based therapeutics such as silver sulfadiazine and thiomersal, as well as polyoxometalates (POMs). Among the mononuclear metal complexes, only a small number of active inhibitors of the S/ACE2 interaction was identified, with titanocene dichloride as the only strong inhibitor. However, among the gold and silver containing complexes many turned out to be very potent inhibitors of PLpro activity. Highly promising activity against both targets was noted for many POMs. Selected complexes were evaluated in antiviral SARS‐CoV‐2 assays confirming activity for gold complexes with N‐heterocyclic carbene (NHC) or dithiocarbamato ligands, a silver NHC complex, titanocene dichloride as well as a POM compound. These studies might provide starting points for the design of metal‐based SARS‐CoV‐2 antiviral agents.

23 January 2017 in European Journal of Inorganic Chemistry
Verified
Journal Article
Closed access
PDF file
APAndrea Pettenuzzo
Andrea Pettenuzzo
RPRebecca Pigot
Rebecca Pigot
LRLuca Ronconi
Luca Ronconi

15 June 2018 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
APAndrea Pettenuzzo
Andrea Pettenuzzo
DMDiego Montagner
Diego Montagner
PMPatrick McArdle
Patrick McArdle
LRLuca Ronconi
Luca Ronconi
With a view to developing more efficient strategies to the functionalization of metallodrugs with carbohydrates, we here report on an innovative and efficient synthetic route to generate gold(III) glycoconjugates in high yields and purity. The method is based on the initial synthesis of the zinc(II)-dithiocarbamato intermediate [ZnII(SSC-Inp-GlcN)2] (Inp = isonipecotic moiety; GlcN = amino-glucose) followed by the transfer of the glucoseisonipecoticdithiocarbamato ligand to the gold(III) center via transmetallation reaction between the zinc(II) intermediate and K[AuIIIBr4] in 1 : 2 stoichiometric ratio, yielding the corresponding glucose-functionalized gold(III)-dithiocarbamato derivative [AuIIIBr2(SSC-Inp-GlcN)]. No protection/deprotection of the amino-glucose scaffold and no chromatographic purification were needed. The synthetic protocol was optimized for glucose precursors bearing the amino function at either the C2 or the C6 position, and works in the case of both α and β anomers. The application of the synthetic strategy was also successfully extended to other metal ions of biomedical interest, such as gold(I) and platinum(II), to obtain [AuI(SSC-Inp-GlcN)(PPh3)] and [PtII(SSC-Inp-GlcN)2], respectively. All compounds were fully characterized by elemental analysis, mid- and far-IR, mono- and multidimensional NMR spectroscopy, and, where possible, X-ray crystallography. Results and potential applications are here discussed.

19 May 2021 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
APAndrea Pettenuzzo
Andrea Pettenuzzo
KVKeti Vezzù
Keti Vezzù
MPMaria Luisa Di Paolo
Maria Luisa Di Paolo
EFEirini Fotopoulou
Eirini Fotopoulou
LMLuciano Marchiò
Luciano Marchiò
LRLuca Ronconi
Luca Ronconi
To develop new metal-based glycoconjugates as potential anticancer agents, four organometallic gold(III)–dithiocarbamato glycoconjugates of the type [AuIII(2-Bnpy)(SSC-Inp-GlcN)](PF6) (2-Bnpy: 2-benzylpyridine; Inp: isonipecotic moiety; GlcN: amino-glucose scaffold; Au3–Au6) and the corresponding model non-glycosylated counterparts [AuIII(2-Bnpy)(SSC-Inp-R)](PF6) (R: OEt (Au1), NH2 (Au2)) have been generated and characterized by means of several analytical techniques (elemental analysis, FT-IR, 1H-/13C-NMR, ESI-MS, UV-Vis, X-ray crystallography). Their stability under physiologically-relevant conditions (PBS solution) and n-octanol/PBS distribution coefficient (D7.4) have also been evaluated. Gold(III) glycoconjugates showed an antiproliferative effect against ovarian carcinoma A2780 cells, with GI50 values in the low micromolar range. Remarkably, their cell growth inhibitory effect increases upon the addition of a glucose transporter 1 (GLUT1) inhibitor, thus ruling out the involvement of GLUT1 in their transport inside the cell. Additional mechanistic studies have been carried out in A2780 cells, supporting the hypothesis of a facilitated diffusion mechanism (possibly mediated by glucose transporters other than GLUT1), and revealing their capability to act as topoisomerase I and II inhibitors and to disrupt mitochondrial membrane integrity, leading to the generation of ROS, thus resulting in the promotion of oxidative stress and, eventually, cell death.

26 August 2025 in ChemBioChem
Verified
Journal Article
Open access
APAndrea Pettenuzzo
Andrea Pettenuzzo
JWJessica Wölker
Jessica Wölker
LMLuciano Marchiò
Luciano Marchiò
IOIngo Ott
Ingo Ott
LRLuca Ronconi
Luca Ronconi
To develop new metal‐based glycoconjugates as potential anticancer agents, three gold(III)‐dithiocarbamato glycoconjugates of the type [Au III Br 2 (SSC‐Inp‐GlcN)] ( Au3‐5 ), their gold(I)‐phosphine counterparts [Au I (SSC‐Inp‐GlcN)(PPh 3 )] ( AuP3‐5 ), and gold(I)‐carbene analogs [Au I (SSC‐Inp‐GlcN)(Et 2 BzImy)] ( AuC3‐5 ) (Inp: isonipecotic moiety; GlcN: amino‐glucose scaffold; Et 2 BzImy: 1,3‐diethylbenzimidazol‐2‐ylidene moiety), as well as the corresponding non‐glycosylated counterparts ( Au1‐2 , AuP1‐2, and AuC1‐2 ) bearing a terminal ester or amide function, are generated and characterized by means of several analytical techniques (FT‐IR, 1 H‐/ 13 C‐NMR, UV–Vis, X‐ray crystallography). Their stability under physiologically relevant conditions (phosphate‐buffered saline solution) has also been evaluated. Contrary to the gold(III)‐glycoconjugates, the glucose‐functionalized gold(I) derivatives show a significant antiproliferative effect against colorectal adenocarcinoma (HT‐29), metastatic breast adenocarcinoma (MDA‐MB‐231), and breast adenocarcinoma (MCF‐7) cells, with IC 50 values in the low micromolar range, the gold(I)‐phosphine derivatives turning up to be the best performers. Cell uptake studies show no evident correlation between cell growth inhibition and cellular uptake, and the use of glucose‐free cell culture media and a GLUT1 inhibitor rules out the involvement of glucose transporters in cell internalization, thus suggesting alternative cell death pathways such as acting at extracellular level (especially for the gold(I) derivatives).

31 July 2023 in Helvetica Chimica Acta
Verified
Journal Article
Open access
JSJoan J. Soldevila‐Barreda
Joan J. Soldevila‐Barreda
APAndrea Pettenuzzo
Andrea Pettenuzzo
MAMaria Azmanova
Maria Azmanova
LRLaia Rafols
Laia Rafols
AAAmr Attia
Amr Attia
APAnaïs Pitto-Barry
Anaïs Pitto-Barry
The synthesis by transmetallation and in‐depth characterisation by IR spectroscopy of five half‐sandwich ruthenium and osmium dithiocarbamato isonipecotamide glycoconjugate complexes are presented herein. The evaluation of their in vitro cytotoxicity and of the zinc precursors’ in vitro cytotoxicity towards ovarian cancer (A2780 and A2780cisR) and normal prostate (PNT2) cells is reported. While the cytotoxicity of the compounds is rather limited, some selectivity is observed.